Advanced search
Publication Cover
Current Medical Research and Opinion Volume 21, 2005 - Issue 9
Submit an article Journal homepage
137
Views
17
CrossRef citations to date
0
Altmetric
Brief Report

Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression

Min-Soo Lee Department of Psychiatry, College of Medicine, Korea University, Seoul, KoreaCorrespondence[email protected]
,
Byung Joo Ham Department of Psychiatry, College of Medicine, Hallym University, Seoul, Korea
,
Baik Seok Kee Department of Psychiatry, College of Medicine, Chung-Ang University, Seoul, Korea
,
Jung‐Bum Kim Department of Psychiatry, Keimyung School of Medicine and Institute for Medical Science, Taegu, Korea
,
Byeong Kil Yeon Department of Psychiatry, Kangdong Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea
,
Kang‐Seob Oh Department of Psychiatry, Kangbuk Samsung Hospital, School of Medicine, Sungkyunkwan University, Seoul, Korea
,
Byoung Hoon Oh Department of Psychiatry, College of Medicine, Yonsei University, Seoul, Korea
,
Chul Lee Department of Psychiatry, College of Medicine, Catholic University of Korea, Seoul, Korea
,
Han Yong Jung Department of Psychiatry, College of Medicine, SoonChunHyang University, Seoul, Korea
,
Ik‐Seung Chee Department of Psychiatry, College of Medicine, Chungnam National University, Taejon, Korea
,
Byeong Moo Choe Department of Psychiatry, College of Medicine, Dong-A University College of Medicine, Pusan, Korea
&
In Ho Paik Department of Psychiatry, College of Medicine, Catholic University of Korea, Seoul, Korea
 show all
Pages 1369-1375 | Accepted 18 Jul 2005, Published online: 02 Aug 2005

Citations (17)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Siegfried Kasper & Gerald Pail. (2010) Milnacipran: a unique antidepressant?. Neuropsychiatric Disease and Treatment 6:sup1, pages 23-31.
Read now
R. Freynhagen, U. Muth-Selbach, P. Lipfert, M. F. Stevens, K. Zacharowski, T. R. Tölle & H.‐J. von Giesen. (2006) The effect of mirtazapine in patients with chronic pain and concomitant depression. Current Medical Research and Opinion 22:2, pages 257-264.
Read now
Raghu Paranthaman & Robert C. Baldwin. (2006) Treatment of psychiatric syndromes due to cerebrovascular disease. International Review of Psychiatry 18:5, pages 453-470.
Read now

Articles from other publishers (14)

Christian P. Cheung, Mathura T. Thiyagarajah, Haben Y. Abraha, Celina S. Liu, Krista L. Lanctôt, Alex J. Kiss, Mahwesh Saleem, Ari Juda, Anthony J. Levitt, Ayal Schaffer, Amy H. Cheung & Mark Sinyor. (2021) The association between placebo arm inclusion and adverse event rates in antidepressant randomized controlled trials: An examination of the Nocebo Effect. Journal of Affective Disorders 280, pages 140-147.
Crossref
Lorenzo Guizzaro, David Dickinson Vaughan Morgan, Andrea Falco & Ciro Gallo. (2020) Hamilton scale and MADRS are interchangeable in meta-analyses but can disagree at trial level. Journal of Clinical Epidemiology 124, pages 106-117.
Crossref
Erita Istriana, Ade Kurnia, Annelies Weijers, Teddy Hidayat, Lucas Pinxten, Cor de Jong & Arnt Schellekens. (2013) Excellent reliability of the Hamilton Depression Rating Scale (HDRS-21) in Indonesia after training. Asia-Pacific Psychiatry 5:3, pages 141-146.
Crossref
Laura R Magni, Marianna Purgato, Chiara Gastaldon, Davide Papola, Toshi A Furukawa, Andrea Cipriani & Corrado Barbui. (2013) Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database of Systematic Reviews.
Crossref
Levent Alev, Alan Lenox-Smith, Murat Altin & Héctor Dueñas. (2013) A Review of the Serotonin-Norepinephrine Reuptake Inhibitors: Pharmacologic Aspects and Clinical Implications for Treatment of Major Depressive Disorder and Associated Painful Physical Symptoms. Open Journal of Depression 02:04, pages 54-63.
Crossref
Philip J Mease, Peter J Zimetbaum, Mei Sheng Duh, Francis Vekeman, Annie Guérin, Mariette Boerstoel-Streefland, Wenjun Jiang & Patrick Lefebvre. (2017) Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data. Annals of Pharmacotherapy 45:2, pages 179-188.
Crossref
Chi-Un Pae, David M. Marks, Manan Shah, Changsu Han, Byung-Joo Ham, Ashwin A. Patkar & Prakash S. Masand. (2009) Milnacipran. Clinical Neuropharmacology 32:6, pages 355-363.
Crossref
Atsuo Nakagawa, Norio Watanabe, Ichiro M Omori, Corrado Barbui, Andrea Cipriani, Hugh McGuire, Rachel Churchill & Toshi A Furukawa. (2009) Milnacipran versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews.
Crossref
Dennis J. Cada, Terri L. Levien & Danial E. Baker. (2009) Milnacipran. Hospital Pharmacy 44:7, pages 604-618.
Crossref
Andrea Cipriani, Toshiaki A Furukawa, Georgia Salanti, John R Geddes, Julian PT Higgins, Rachel Churchill, Norio Watanabe, Atsuo Nakagawa, Ichiro M Omori, Hugh McGuire, Michele Tansella & Corrado Barbui. (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. The Lancet 373:9665, pages 746-758.
Crossref
Atsuo Nakagawa, Norio Watanabe, Ichiro M Omori, Corrado Barbui, Andrea Cipriani, Hugh McGuire, Rachel Churchill & Toshi A Furukawa. (2008) Efficacy and Tolerability of Milnacipran in the Treatment of Major Depression in Comparison with??Other Antidepressants. CNS Drugs 22:7, pages 587-602.
Crossref
George I. Papakostas, Michael E. Thase, Maurizio Fava, J. Craig Nelson & Richard C. Shelton. (2007) Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents. Biological Psychiatry 62:11, pages 1217-1227.
Crossref
George I. Papakostas & Maurizio Fava. (2007) A meta-analysis of clinical trials comparing milnacipran, a serotonin–norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. European Neuropsychopharmacology 17:1, pages 32-36.
Crossref
. (2006) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 15:3, pages i-xii.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.